🕒 Last update: loading…16/11/2026

Stock Thermo Fisher Scientific Inc. TMO

Thermo Fisher Scientific Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 03/10/2026.

  • ✅ Price trend passed
  • ✅ Growth passed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 45.17%

Price change 2019 → 2020: 43.37%

Price change 2020 → 2021: 43.25%

Price change 2021 → 2022: -17.47%

Price change 2022 → 2023: -3.61%

Price change 2023 → 2024: -1.99%

Price change 2024 → 2025: 11.38%

Price change 2025 → 2026: 12.61%

Price change 2026 (year to date): 10.13%

Financial growth

Revenue CAGR (8 years): 9.01%

Earnings CAGR (8 years): 12.59%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.74

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 28.27

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 3.99% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Thermo Fisher Scientific Inc.30.00.74+9.9 %🔒
Amgen Inc.20.66.31+6.1 %–
AstraZeneca PLC20.10.61+3.9 %–
Roche Holding AG25.80.98+1.7 %–
UnitedHealth Group Incorporated21.10.83+10.9 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Thermo Fisher Scientific Inc. over the latest fiscal years.

Revenue
44.6 bn USD
fiscal year 2025
Net income
6.7 bn USD
fiscal year 2025
Net margin
15.1 %
fiscal year 2025
Average annual growth
+6.7 %
Revenue growth over 5 years
Average annual growth
+10.1 %
Revenue growth over 10 years
Market cap
259 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202032.2 bn6.4 bn19.8 %n/a
202139.2 bn7.7 bn19.7 %+21.7 %
202244.9 bn7.0 bn15.5 %+14.5 %
202342.9 bn6.0 bn14.0 %-4.6 %
202442.9 bn6.3 bn14.8 %+0.1 %
202544.6 bn6.7 bn15.1 %+3.9 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Thermo Fisher Scientific Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
4.19
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
446.24 USD
DCF below share price · share price 704.88 USD, gap -36.7 %
Net Debt / EBITDA
3.19 x
high debt
Fiscal year20212022202320242025
Cash and investments4.5 bn8.5 bn8.1 bn5.6 bn10.1 bn
Total Debt36.3 bn36.1 bn36.4 bn32.8 bn39.4 bn
Net Debt31.9 bn27.5 bn28.3 bn28.8 bn29.5 bn
Equity40.8 bn44.0 bn46.7 bn49.6 bn53.4 bn
Total assets95.1 bn97.2 bn98.7 bn97.3 bn110 bn
Operating cash flow9.5 bn9.2 bn8.4 bn8.7 bn7.8 bn
Investments (capex)2.5 bn2.2 bn1.5 bn1.4 bn1.5 bn
Free cash-flow7.0 bn6.9 bn6.9 bn7.3 bn6.3 bn
Share buybacks2.0 bn3.0 bn3.0 bn4.0 bn3.0 bn
Dividends paid395 m455 m523 m583 m636 m

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)36.83 x
Price / book value4.73 x
Return on Equity (ROE)13.3 %
Return on Invested Capital (ROIC)7.5 %
Net margin15.0 %
Debt / equity0.76 x
Current ratio1.81 x
Interest coverage5.54 x
Free cash-flow yield2.9 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Thermo Fisher Scientific Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
30.2
close to the sector
Sector median P/E
27.7
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Thermo Fisher Scientific Inc.257 bn30.015.1 %
Danaher Corporation DHR162 bn28.914.7 %
Agilent Technologies, Inc. A49.3 bn30.118.8 %
Revvity, Inc. RVTY17.3 bn29.08.5 %
Bio-Rad Laboratories, Inc. BIO10.3 bn41.129.4 %
Waters Corporation WAT44.9 bn33.520.3 %
Bio-Techne Corporation TECH11.4 bn37.56.0 %
Qiagen N.V. QGEN10.4 bn20.820.3 %
Mettler-Toledo International Inc. MTD34.5 bn39.621.6 %
Sector median (NYSE)27.7

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Thermo Fisher Scientific Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
43 analysts
Average price target
707.29 USD
from 520.00 USD to 810.00 USD, 37 targets over 12 months
Gap with the share price
+1.8 %
price 694.76 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 36hold 7sell 0strong sell 0

Analysts' average target 707.29 USD, DCF value 446.24 USD, share price 694.76 USD.

Average target over the last 3 months: 758.93 USD (15 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202648.0 bn9.5 bn25.28 (25.17 / 25.42)27.515
202750.6 bn10.2 bn27.73 (26.93 / 29.21)25.116
202853.8 bn11.2 bn30.61 (27.37 / 32.35)22.76

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
30/10/2026Argus ResearchBuyBuy
23/10/2026CitigroupBuyBuy
22/10/2026BairdOutperformOutperform
22/10/2026RBC CapitalSector PerformSector Perform
22/10/2026BarclaysOverweightOverweight

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Thermo Fisher Scientific Inc.: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
0.470 USD
ex-dividend on 15/12/2026
Last 12 months
1.84 USD
number of payments: 4
Yield
0.3 %
on the last known price
Years of increases
9
consecutive
Years of payments
14
uninterrupted

● Next ex-dividend date: 15/12/2026, 0.470 USD per share.

00.470.941.411.882007 : 0.0000 USD2008 : 0.0000 USD20082009 : 0.0000 USD2010 : 0.0000 USD20102011 : 0.0000 USD2012 : 0.540 USD20122013 : 0.600 USD2014 : 0.600 USD20142015 : 0.600 USD2016 : 0.600 USD20162017 : 0.600 USD2018 : 0.680 USD20182019 : 0.760 USD2020 : 0.880 USD20202021 : 1.04 USD2022 : 1.20 USD20222023 : 1.40 USD2024 : 1.56 USD20242025 : 1.72 USD2026 : 1.88 USD2026

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
15/12/20260.470 USD15/01/2027
15/09/20260.470 USD15/10/2026
15/06/20260.470 USD15/07/2026
13/03/20260.470 USD15/04/2026
15/12/20250.430 USD15/01/2026
15/09/20250.430 USD15/10/2025
13/06/20250.430 USD15/07/2025
14/03/20250.430 USD15/04/2025

Earnings releases

DatePublished EPSExpected EPSSurprise
21/10/20266.686.40+4.4 %
23/07/20266.035.72+5.4 %
23/04/20265.445.25+3.6 %
29/01/20266.576.45+1.9 %
22/10/20255.795.50+5.3 %
23/07/20255.365.23+2.5 %

Stock splits

DateOperation
06/06/1996split: 3 shares for 2
25/05/1995split: 3 shares for 2
29/10/1993split: 3 shares for 2
03/11/1986split: 3 shares for 2
17/09/1985split: 3 shares for 2
04/01/1984split: 3 shares for 2

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Thermo Fisher Scientific Inc.

Free float
99.7 %
share of freely traded shares
Institutions
91.4 %
2,714 declared holders, 2026Q2
Large funds tracked
37
hold the stock as of 2026Q2
Executives (insiders)
0 / 94
0 purchases, 94 sales in 130 days
US elected officials
15
7 purchases, 8 sales in 12 months

Indices: S&P 500 (since 03/08/2004).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group34.1 m19.8 bn0.3 %+0.9 %2025Q4
State Street33.7 m16.9 bn0.2 %+101.1 %2026Q2
BlackRock30.9 m15.5 bn0.2 %+1.6 %2026Q2
Fidelity14.1 m7.1 bn0.3 %+30.7 %2026Q2
Morgan Stanley10.8 m5.4 bn0.3 %-0.9 %2026Q2
JPMorgan Chase8.5 m4.3 bn0.2 %+25.1 %2026Q2
Geode Capital Management8.4 m4.2 bn0.2 %-0.3 %2026Q2
Capital World Investors6.2 m3.1 bn0.4 %-6.8 %2026Q2

Latest insider transactions

DatePersonSideAmount
28/10/2026Britt Lisa P.sale2.0 m USD
31/08/2026Pettiti Gianlucasale245,752 USD
31/08/2026Pettiti Gianlucasale2.3 m USD
24/08/2026Casper Marc Nsale63,166 USD
24/08/2026Casper Marc Nsale20,677 USD
24/08/2026Casper Marc Nsale49,613 USD

Elected officials' disclosures

DateOfficialSideAmount
13/10/2026Ro Khannasale$15,001 - $50,000
07/08/2026Ro Khannapurchase$1,001 - $15,000
12/12/2024Michael Rullisale$1,001 - $15,000
27/03/2026Alan Armstrongpurchase$1,001 - $15,000
10/07/2026Daniel Milton Newhousesale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 17/03/1980
ISIN code
US8835561023
Workforce
125,000
full-time employees
Chief executive
Marc N. Casper
Next earnings
04/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Thermo Fisher Scientific Inc.

What is the Thermo Fisher Scientific Inc. share price?

Latest recorded price: 700.22 USD on 13/11/2026, for a market cap of 259 bn USD.

What is the revenue of Thermo Fisher Scientific Inc.?

44.6 bn USD for fiscal year 2025, with net income of 6.7 bn USD (net margin 15.1 %).

Does Thermo Fisher Scientific Inc. pay a dividend?

Yes. Latest dividend: 0.470 USD per share, ex-dividend on 15/12/2026. Over 12 months: 1.84 USD. Yield on the latest known price: 0.3 %.

When does Thermo Fisher Scientific Inc. report its next earnings?

The next release is expected on 04/02/2027. EPS expected by analysts: 7.13.

What do analysts say about Thermo Fisher Scientific Inc.?

Out of 43 analysts: 36 buy or strong buy, 7 hold, 0 sell or strong sell. Average price target: 707.29 USD, i.e. +1.8 % from the share price.

What is the P/E ratio of Thermo Fisher Scientific Inc.?

Trailing 12-month P/E of 30.2, against 27.7 for the sector median on the same exchange (10-year median: 22.3).

Is Thermo Fisher Scientific Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US8835561023).

How many employees does Thermo Fisher Scientific Inc. have?

125,000 full-time employees according to the latest published profile.

Who runs Thermo Fisher Scientific Inc.?

Marc N. Casper is the company's chief executive.

Which large funds own Thermo Fisher Scientific Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, Fidelity, Morgan Stanley.

07

Similar stocks